We also detected good effectiveness of PAL2 (p < 0.05) for PFS prognosis inside four LGG subgroups: with wtIDH, mutant IDH, mutant IDH with 1p/19q codeletion (p < 0.05) and methylated MGMT, and in GBM subgroups with wtIDH and with unmethylated MGMT promoter. The gene discussed is MGMT; the disease is glioblastoma.